Severity
Moderate
FDA Drug recall · Reported May 29, 2024
Subpotent product in addition to having out-of-specification results for impurities.
American Regent, Inc. recalled Vasopressin Injection, USP, 200 Units per 10 mL (20 Units per mL), 10 mL Multiple-Dose Vi… - a moderate-severity action.
Vasopressin Injection, USP, 200 Units per 10 mL (20 Units per mL), 10 mL Multiple-Dose Vi… was recalled by American Regent, Inc. in May 29, 2024. Reason: Subpotent product in addition to having out-of-specification results for impurities.. Check the official notice for the remedy. Verify recall #D-0507-2024 with the FDA Drug before acting.
The recall
American Regent, Inc. issued this moderate-severity FDA Drug recall-Subpotent product in addition to having out-of-specification results for impurities..
Sourced from official FDA Drug enforcement records. Verify recall #D-0507-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0507-2024) was formally reported on May 29, 2024, with the manufacturer initiating the action on May 13, 2024. It is classified under Moderate severity (Class II), with a current status of Terminated. American Regent, Inc. is listed as the recalling firm, operating out of New Albany, OH. Federal records list the affected scope as 2,352 vials.
The documented reason for this recall is: Subpotent product in addition to having out-of-specification results for impurities. Distribution data in the federal record shows the product reached: USA Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
2,352 vials
Related Recalls
6
5 from same agency
Vasopressin Injection, USP, 200 Units per 10 mL (20 Units per mL), 10 mL Multiple-Dose Vial, Rx only, For Intravenous Infusion, American Regent, Inc., Shirley, NY 11967, NDC 0517-1030-01
Subpotent product in addition to having out-of-specification results for impurities.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0507-2024 |
| Date reported | May 29, 2024 |
| Date initiated | May 13, 2024 |
| Recalling firm | American Regent, Inc. |
| Firm location | New Albany, OH |
| Affected scope | 2,352 vials |
| Distribution | USA Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported May 29, 2024. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.